Centene Details 2025 Underperformance, Zero Payout for Long-Term Executive Incentives, and Board's Opposition to Independent Chairman Mandate
summarizeSummary
Centene's definitive proxy statement reveals a substantial 2025 net loss and a 70% drop in adjusted EPS, resulting in no payout for long-term executive incentives, while the board opposes a mandated independent chairman.
check_boxKey Events
-
Annual Shareholder Meeting Scheduled
Centene Corporation will hold its Annual Meeting of Stockholders on May 12, 2026, to vote on director elections, executive compensation, auditor ratification, and a stockholder proposal.
-
Significant 2025 Financial Underperformance
The company reported a GAAP net loss of $6.67 billion for fiscal year 2025, primarily due to a $6.7 billion goodwill impairment, and Adjusted Diluted EPS decreased by 70% to $2.08.
-
No Payout for Long-Term Executive Incentives
Executive officers received no payout for their 2023-2025 performance-based restricted stock units (PSUs) as performance conditions were not met, reflecting the company's pay-for-performance philosophy amidst poor results.
-
Shift in 2026 Compensation Strategy
For 2026, annual cash incentives will incorporate Health Benefits Ratio (HBR) to prioritize margin expansion, and long-term PSUs will be 100% tied to absolute Total Shareholder Return (TSR) over three years.
auto_awesomeAnalysis
This definitive proxy statement outlines Centene's significant financial underperformance in 2025, including a GAAP net loss of $6.67 billion and a 70% decrease in Adjusted Diluted EPS. This poor performance directly led to no payout for the 2023-2025 long-term executive performance stock units (PSUs) and a below-target payout for the 2025 annual cash incentive plan. The company is responding by shifting its 2026 compensation strategy to prioritize margin expansion and absolute Total Shareholder Return (TSR) for long-term incentives. Additionally, the Board is recommending against a stockholder proposal to mandate an independent board chairman, highlighting ongoing governance discussions amidst past stock price declines and legal challenges mentioned in the proposal.
At the time of this filing, CNC was trading at $33.40 on NYSE in the Finance sector, with a market capitalization of approximately $16.5B. The 52-week trading range was $25.08 to $66.03. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.